Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1.

Liver cirrhosis is often accompanied by a disturbed carbohydrate metabolism similar to type 2 diabetes. To investigate the severity of the defect in insulin secretion in this form of diabetes, we measured insulin release from isolated pancreatic islets of rats with CCl(4)-phenobarbital-induced liver cirrhosis. Cirrhosis was confirmed by clinical signs, elevated liver enzymes and histology. Fasting venous plasma glucose concentrations were equal in rats with liver cirrhosis and in controls. Plasma insulin and glucagon concentrations were significantly greater (P<0.01) in cirrhotic rats than in control animals. Glucose (16.7 mM)-induced stimulation of insulin release from pancreatic islets revealed a twofold increase in control and cirrhotic rats. Basal and stimulated insulin secretion, however, were significantly lower in cirrhotic animals. The incretin hormone, glucagon-like peptide-1 (GLP-1), has therapeutic potential for the treatment of type 2 diabetes. Therefore, islets from control and cirrhotic animals were incubated with GLP-1 in concentrations from 10(-)(11) to 10(-)(6) M. GLP-1 stimulated insulin release in a concentration-dependent manner. In islets from cirrhotic rats, basal and stimulated insulin secretion was blunted compared with controls. These data show that the hyperinsulinemia observed in liver cirrhosis is not due to an increase of insulin secretion from islets, but could be explained by decreased hepatic clearance of insulin. GLP-1 may ameliorate diabetes in patients with liver cirrhosis.

[1]  J. Bruix,et al.  Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis , 1985, Hepatology.

[2]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[3]  R. Sheppard,et al.  Peptide Synthesis. Part 8. A System for Solid-phase Synthesis Under Low Pressure Continuous Flow Conditions. , 1986 .

[4]  R. Casamitjana,et al.  Hyperglucagonism and glucagon resistance in cirrhosis. Paradoxical effect of propranolol on plasma glucagon levels. , 1988, Journal of hepatology.

[5]  C. Orskov.  Glucagon-like peptide-1, a new hormone of the entero-insular axis. , 1992, Diabetologia.

[6]  K. Sirinek,et al.  Glucose intolerance and hyperinsulinemia of cirrhosis are not results of spontaneous or surgical portosystemic shunting. , 1991, American journal of surgery.

[7]  P. Pizcueta,et al.  Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation , 1994, Hepatology.

[8]  R. Sheppard,et al.  Peptide synthesis. Part 8. A system for solid-phase synthesis under low pressure continuous flow conditions , 1986 .

[9]  E. Neufeld,et al.  CARBOHYDRATE METABOLISM. , 1965, Annual review of biochemistry.

[10]  R. Sherwin,et al.  Carbohydrate homeostasis, liver and diabetes. , 1976, Progress in liver diseases.

[11]  C. Holdsworth,et al.  The effect of portacaval anastomosis on oral carbohydrate tolerance and on plasma insulin levels , 1972, Gut.

[12]  N. Mcintyre,et al.  Glucose and Insulin Metabolism in Cirrhosis , 1995 .

[13]  A. Meyer-Alber,et al.  Mechanism of insulin resistance in CCl4-induced cirrhosis of rats. , 1992, Gastroenterology.

[14]  J. Schrezenmeir,et al.  Biological activity of GLP-1-analogues with N-terminal modifications , 1999, Regulatory Peptides.

[15]  T. Nakamura,et al.  Pancreatic endocrine function in cirrhotic rats. , 1988, Metabolism: clinical and experimental.

[16]  L. B. Knudsen,et al.  Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. , 1996, European journal of pharmacology.

[17]  R. DeFronzo,et al.  Glucose metabolism in cirrhosis: a review with some perspectives for the future. , 1989, Diabetes/metabolism reviews.

[18]  C. Lang.  Mechanism of Insulin Resistance in Infection , 1993 .

[19]  N. Mcintyre,et al.  Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients. , 1998, Journal of hepatology.

[20]  J. Smith,et al.  Modification of Glucose-Induced Insulin Release by Alteration of pH , 1983, Diabetes.

[21]  R. Hartung.  Dose—Response Relationships , 1987 .

[22]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[23]  K. Wiechel,et al.  Insulin uptake by the human alcoholic cirrhotic liver. , 1985, Metabolism: clinical and experimental.

[24]  D. Nathan,et al.  Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects , 1992, Diabetes Care.

[25]  R. Pérez Tamayo.  Is cirrhosis of the liver experimentally produced by CCl4 and adequate model of human cirrhosis? , 1983, Hepatology.

[26]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[27]  A. Yates,et al.  Stimulus-secretion coupling of arginine-induced insulin release , 2000, Endocrine.

[28]  Å. Danielsson,et al.  Insulin secretion in pancreatic islets from rats with cirrhosis. , 1994, Journal of hepatology.

[29]  A. Boschero,et al.  The stimulus-secretion coupling of glucose-induced insulin release. Metabolic and functional effects of NH4+ in rat islets. , 1978, The Journal of clinical investigation.

[30]  N. Mcintyre,et al.  Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis , 1991, Hepatology.

[31]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[32]  J. Holst,et al.  Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients , 1996, Diabetes Care.

[33]  Elizabeth S. Pietras,et al.  Chronic Hepatitis: An Update on Terminology and Reporting , 1996 .

[34]  W. Creutzfeldt,et al.  Isolation and primary structure of tumor-derived peptides related to human pancreastatin and chromogranin A. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Heine,et al.  Insulin action in cirrhosis , 1985, Hepatology.